Ignite Creation Date:
2024-05-06 @ 10:06 AM
Last Modification Date:
2024-10-26 @ 12:24 PM
Study NCT ID:
NCT03164694
Status:
RECRUITING
Last Update Posted:
2018-07-30
First Post:
2017-05-22
Brief Title:
APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC
Sponsor:
Sun Yat-sen University
Organization:
Sun Yat-sen University
Study Overview
Official Title:
A Multicenter Phase II Trial of Pemetrexed Plus Carboplatin With or Without Apatinib in Patients With Advanced Non-small Cell Lung Cancer Without EGFR Mutation ALK Gene Rearrangement and ROS1 Gene Rearrangement
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
APPEAL
Brief Summary:
The purpose of this study is to studying the addition of apatinib with chemotherapy to investigate the efficacy and safety of apatinib in combination with chemotherapy in patients with advanced NSCLC
Detailed Description:
Platinum-based chemotherapy is the recommended therapeutic approach for patients with advanced non-small cell lung cancer NSCLC without EGFR mutation ALK gene rearrangement and ROS1 gene rearrangement However the prognosis of advanced NSCLC remains poor Apatinib is a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2 Apatinib has been proved to be effective and safe in heavily pretreated patients with gastric cancer This study is to studying the addition of apatinib with chemotherapy to investigate the efficacy and safety of apatinib in combination with chemotherapy in patients with advanced NSCLC
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None